CG
CRSP icon

Caprock Group’s CRISPR Therapeutics CRSP Stock Holding History

Caprock Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$221K Buy
4,650
+483
+12% +$25.5K 0.01% 1023
2025
Q4 		$219K Buy
4,167
+153
+4% +$9.16K ﹤0.01% 1089
2025
Q3 		$208K Buy
+4,014
New +$230K 0.01% 1053

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Caprock Group's CRSP Position: Q1 2026 in Review

Caprock Group increased its CRISPR Therapeutics (CRSP) stake by 12% in Q1 2026, buying an estimated $25.5K and bringing the position to 4,650 shares worth $221K. The position accounts for 0.01% of the portfolio, ranked #1023.

Caprock Group first reported a position in CRSP in Q3 2025 and has held it in 3 quarters since. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Caprock Group held 4,650 shares of CRISPR Therapeutics worth $221K as of Q1 2026.
  • Caprock Group bought 483 CRISPR Therapeutics shares in Q1 2026, an estimated $25.5K.
  • CRISPR Therapeutics made up 0.01% of Caprock Group's portfolio in Q1 2026, its #1023 holding.
  • Caprock Group first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Caprock Group's 13F filing for Q1 2026, filed 11 May 2026.